Circumferential and focal ablation of Barrett's esophagus containing dysplasia

American Journal of Gastroenterology

Volumn 104, Issue 2, 2009, Pages 310-317

  Sharma, Virender K ^a   Jae Kim, H ^a   Das, Ananya ^a   Wells, Christopher D ^a   Nguyen, Cuong C ^a   Fleischer, David E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ACETYLCYSTEINE; ESOMEPRAZOLE; PROTON PUMP INHIBITOR; WATER;

ADULT; AGED; ARTICLE; BALLOON CATHETER; BARRETT ESOPHAGUS; CATHETER ABLATION; DEVICE; DRUG MEGADOSE; DYSPLASIA; ELECTRODE; ENDOSCOPE; ENDOSCOPIC BIOPSY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SURGERY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; BARRETT ESOPHAGUS; CATHETER ABLATION; ENDOSCOPY; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METAPLASIA; MIDDLE AGED; MUCOUS MEMBRANE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 59749094369     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.142     Document Type: Article

References (43)

1. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
2. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
3. Eisen GM, Sandler RS, Murray S et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997;92:27-31.
4. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997;92:1293-7.
5. Cameron AJ, Souto EO, Smyrk TC. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroenterol 2002;97:1375-80.
6. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Human Pathol 2001;32:379-88.
7. Blot WJ, Devesa SS, Kneller RW et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
8. Bollschweiler E, Wolfgarten E, Gutschow C et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92:549-55.
9. Sharma VK, Chockalingam H, Hornung CA et al. Changing trends in esophageal cancer: a 15-year experience in a single center. Am J Gastroenterol 1998;93:702-5.
10. Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
11. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
12. Lao CD, Simmons M, Syngal S, et al., Fortlage L Dysplasia in Barrett esophagus. Cancer 2004;100:1622-7.
13. Spechler SJ. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 2005;100:927-35.
14. Gerson LB, Ullah N, Hastie T et al. Does cancer risk affect health-related quality of life in patients with Barrett's esophagus? Gastrointest Endosc 2007;65:16-25.
15. Shaheen NJ, Dulai GS, Ascher B et al. Effect of a new diagnosis of Barrett's esophagus on insurance status. Am J Gastroenterol 2005;100:577-80.
16. Spechler SJ. Barrett's Esophagus. N Engl J Med 2002;346:836-42.
17. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-7; discussion 387-8.
18. Peters HJ, Clark GW, Ireland AP et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-21; discussion 821-2.
19. van Sandick JW, van Lanschot JJ, Kuiken BW et al. Im pact of endoscopic biopsy surveillance of Barrett oesophagus on pathological stage and clinical outcome of Barrett carcinoma. Gut 1998;43:216-22.
20. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000;321:1252-5.
21. Conio M, Blanchi S, Lapertosa G et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931-9.
22. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
23. Inadomi JM, Sampliner R, Lagergren J et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138:176-86.
24. Dulai GS, Jensen DM, Cortina G, et al., Ippoliti A Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 2005;61:232-40.
25. Ganz RA, Utley DS, Stern RA et al. Complete ablation of esophageal epithelium with a balloon-based bipolar electrode: a phased evaluation in the porcine and in the human esophagus. Gastrointest Endosc 2004;60:1002-10.
26. Dunkin BJ, Martinez J, Bejarano PA et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device (BÂRRX). Surg Endosc 2006;20:125-30.
27. Smith CD, Bejarano PA, Melvin WS et al. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc 2007;21:560-9.
28. Sharma VK, Kim HJ, Das A et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 2008;40:380-7.
29. Gopal DV, Lieberman DA, Magaret N et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003;48:1537-41.
30. Skacel M, Petras RE, Gramlich TL et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
31. Reid BJ, Levine DS, Longton G et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
32. Weston AP, Banerjee SK, Sharma P et al. p53 protein overexpression in low grade dysplasia (LGD) in Barett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
33. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
34. Dulai GS, Shekelle PG, Jensen DM et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 2005;100:775-83.
35. Lee RB, Miller JI. Esophagectomy for cancer. Surg Clin N Am 1997;77:1169-96.
36. Bolton JS, Fuhrman GM, Richardson WS. Esophageal resection for cancer. Surg Clin N Am 1998;78:773-94.
37. Dimick JB, Cattaneo SM, Lipsett PA et al. Hospital volume is related to clinical and economic outcomes of esophageal resection in Maryland. Ann Thorac Surg 2001;72:334-40.
38. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized III trial. Gastrointest Endosc 2005;62:488-98.
39. Gondrie RE, Pouw CM, Sondermeijer T et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40:370-9.
40. Gondrie JJ, Rygie AM, Sondermeijer C et al. Balloon-based circumferential ablation followed by focal ablation of Barrett esophagus containing high-grade dysplasia effectively removes all genetic alterations. Gastroenterology 2007;132 S1: A-64.
41. Ganz RA, Overholt BF, Sharma VK et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: A U.S. multicenter registry. Gastrointest Endosc 2008;68:35-40.
42. Shaheen NJ, Sharma P, Overholt BF et al. A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett's esophagus (BE) containing dysplasia: interim results of the AIM dysplasia trial. Gastroenterology 2008;134:A37.
43. Inadomi JM, Madanick RD, Somsouk M et al. Radiofrequency ablation is more cost-effective than endoscopic surveillance or esophagectomy among patients with Barrett's esophagus and low-grade dysplasia. Gastroenterology 2007;132:A-53.